|Day Low/High||167.23 / 176.49|
|52 Wk Low/High||90.14 / 179.65|
Jim Cramer lists the great stocks and the obvious winners he wishes he had talked about more.
My trading strategy for GWPH whether you are currently long or want to be.
And why I won't recommend any other stocks in these markets, right now.
Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.
GWPH is ready to float higher after some sideways consolidation.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
Jim Cramer weighs in on Brinks, Sangamo Biosciences, Medtronic, Fiat Chrysler, GW Pharmaceuticals, EPR Properties.
The main reason most cannabis-related concerns head north to list their shares is banking.
Despite the current stock market, investors are still looking for ways to play the new legalization of hemp.
DALLAS, December 19, 2018 /PRNewswire/ -- Kali, Inc. (Kali, Inc.
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
A potential great pipeline but let's check the charts.
Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
As cannabis becomes increasingly legalized in a recreational and medicinal capacity, what actually are the side effects of marijuana? Experts told TheStreet the things you need to know about how the plant affects you.
These names should stoke up your portfolio.
On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.
These stocks offer some diversification or unique features in the legal-weed space.
The DEA will now classify certain drug products to containing cannabidiol as schedule V.
Sales trends and the potential for stronger versions of prescription cannabis offer medical marijuana providers hope.
Cannabidiol, or CBD, is a cannabis extract that's used to treat everything from pain to opiate addiction to PTSD. It doesn't get you high -- but advocates say that's the reason that CBD could soon eclipse the multibillion-dollar pot industry.
Marijuana has gone from an ancient medicinal herb to an edible gummy bear -- but how has the plant's tumultuous past impacted its future market?
In recent trading, shares of GW Pharmaceuticals plc have crossed above the average analyst 12-month target price of $168.88, changing hands for $170.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.
THC is the psychoactive ingredient in marijuana that produces the feeling of being high. But, THC also has other applications that include health benefits and some side effects.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?
Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.